Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Erjan Wang"'
Autor:
Hossein Borghaei, Erjan Wang, Antonello Abbattista, Corrado Gallo Stampino, Marina Carpentieri, Francesco Bertolini, Cristina Noberasco, Andrej Lyshchik, Filippo G. de Braud, Jordan D. Berlin, Roger B. Cohen, Laura W. Goff
Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520f17646a23bb84a305072cdbb334de
https://doi.org/10.1158/1078-0432.c.6523301.v1
https://doi.org/10.1158/1078-0432.c.6523301.v1
Autor:
Hossein Borghaei, Erjan Wang, Antonello Abbattista, Corrado Gallo Stampino, Marina Carpentieri, Francesco Bertolini, Cristina Noberasco, Andrej Lyshchik, Filippo G. de Braud, Jordan D. Berlin, Roger B. Cohen, Laura W. Goff
Additional Methods; Tables and Figure [1]Supplementary Methods: Contrast-enhanced ultrasound (CE-US) [2]Supplementary Table S1. Pharmacokinetic characteristics of PF-03446962 following single-dose administration in cycle 1 [3]Supplementary Table S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbbbff94b4054d7544cbe95be39dcd4
https://doi.org/10.1158/1078-0432.22456403
https://doi.org/10.1158/1078-0432.22456403
Autor:
Cristina Noberasco, Roger B. Cohen, Marina Carpentieri, Francesco Bertolini, Filippo de Braud, Laura W. Goff, Hossein Borghaei, Jordan Berlin, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, Andrej Lyshchik
Publikováno v:
Clin Cancer Res
Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity
Autor:
Filippo de Braud, Cristina Noberasco, Wendy J. Levin, Corrado Gallo Stampino, Erjan Wang, Laura W. Goff, Roger B. Cohen, Dana D. Hu-Lowe, Jordan Berlin, Hossein Borghaei, Antonello Abbattista
Publikováno v:
Molecular Cancer Therapeutics. 10:A1-A1
Background: Transforming Growth Factor β (TGF β) is a cytokine able to regulate many biological processes in cancer. At the vascular level, the activity of TGFβ is exerted by selectively binding to its receptor, activin receptor like kinase 1 (ALK